CTXR

Citius Pharmaceuticals, Inc. (CTXR) | Rumor.io

Citius Pharmaceuticals

CTXR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,858

Bullish sentiment (50-day avg)37%

Price to earnings ratio-0.16

Market capitalization15.1M

Earnings per share-1.75

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-39.7M

Social

What share of all stock conversation is about CTXR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 5

Citius Pharmaceuticals, Inc. reports strong commercial progress for LYMPHIR, its FDA-approved cancer treatment for relapsed/refractory cutaneous T-cell lymphoma, with new institutions ordering LYMPHIR increasing 78% quarter-over-quarter.
LYMPHIR is now available in 42 institutions, and the company estimates the CTCL market opportunity exceeds $400M, with a $14.10M market cap and 4.98M shares short, representing 18.48% of the float.
Citius Oncology's commercial momentum is driven by rising repeat vial orders from healthcare providers, alongside near 100% insurer coverage, ahead of their full sales force rollout, with a 78% QoQ surge in ordering accounts across 42 top US cancer centers.

Generated by AI

Sentiment

Of the messages about CTXR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -39.22	52.32% +3.66
Bearish	—	—	100% +39.22	47.68% -3.66

Bullish· Jun 27

$CTXR is expected to have greater highs and will eventually reach its full potential.
Citius Pharmaceuticals, Inc. (CTXR) is a prime acquisition target for CRMD, with a potential deal worth $50-100M.
$CTXR is expected to distribute its shares, with some speculating that it may be acquired by CRMD or distributed to CTOR shareholders.

Bearish· Jun 9

$CTXR is trading at a low average price of $36.75 due to a high risk-to-reward ratio, making it a high-risk investment.
The stock has a history of experiencing pump and dump schemes, leading to significant price drops and potential losses for investors.
Short sellers are actively taking control of the low volume, which could lead to a sell-off and further price declines.

Generated by AI

Topics

Of the messages about CTXR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	80%	87.31%
Analysts	—	—	20%	0.93%
Controversies	—	—	0%	0.93%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	10.84%

Announcements· Jun 9

Citius Pharmaceuticals' subsidiary, Citius Oncology, has entered into a distribution services agreement with Cardinal Health to support the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma.
The agreement with Cardinal Health will provide specialty pharmaceutical distribution services, and the LYMPHIR launch is expected to be supported by the secured J-code and the distribution deal.
Citius Pharmaceuticals has also announced an increase in authorized shares from 26,000,000 to 260,000,000, and the redemption of one share of Series A Preferred Stock for $100.

Technical Analysis· Jun 9

$CTXR is forming a bullish cup and handle pattern, and the author is watching for a potential breakout.
The stock has experienced a significant price increase, with a 170%+ gain, and the author is watching for a potential continuation of the upward momentum.
The author is expecting $CTXR to break $1.75, which could lead to a move to $2.50.

Generated by AI

Community

Of the messages about CTXR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	63.86%
Newcomers	—	—	0%	36.14%

Regulars· May 21

Citius Pharmaceuticals achieves primary and secondary endpoints in Phase 3 trial of Mino-Lok Antibiotic Lock Solution, meeting a statistically significant improvement in time to failure event compared to control arm patients.
The stock price is not holding well despite the positive trial results, with many shares registered to sell near the $1 mark, potentially leading to a 15c pop.
Citius Pharmaceuticals' Phase 3 trial of Mino-Lok Antibiotic Lock Solution has been completed, with the press release issued this morning, and the company's shares are being closely watched for potential swing plays.

Newcomers· Jun 11

New investors are excited about Citius Pharmaceuticals' strategic financing, which will help with the commercial launch of LYMPHIR.
The influx of $15.8M in funding is seen as a positive development for the company's future prospects.
This news is sparking interest in CTXR stock, with some newcomers considering it a potential investment opportunity.

Generated by AI

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one investor meetings at two upcoming investor conferences in New York City.

27d agoYahoo Finance

Citius Pharmaceuticals Receives Nasdaq Extension to Regain Compliance

Detailed price information for Citius Pharmaceuticals Inc (CTXR-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

H.C. Wainwright reiterates Citius Pharmaceuticals stock rating at buy

1mo agoInvesting.com

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology Inc. (NASDAQ:CTOR) shares fell 10.

1mo agoYahoo Finance

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update.

1mo agoYahoo Finance

Also Discussed

Investors talking about CTXR also mention

#	Name	Attention
1	ASRT - Assertio Holdings, Inc.	——
2	Senseonics Holdings, Inc.SENS	0%+0
3	VCNX - Vaccinex, Inc.	——
4	OBSV - ObsEva S.A.	——
5	Atossa Genetics IncATOS	0%0
6	CorMedix Inc.CRMD	0%+0
7	Soligenix Inc.SNGX	0%0
8	Motus GI Holdings Inc.MOTS	0%new
9	TENK - TenX Keane Acquisition Ordinary Share	——
10	Entera Bio Ltd.ENTX	0%new

Citius Pharmaceuticals, Inc.

Healthcare
Biotechnology

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing critical care products for specialized medical needs. Citius Pharmaceuticals, Inc. concentrates on areas such as oncology, anti-infectives, adjunct cancer care, prescription products, and stem cell therapy. Its current portfolio includes LYMPHIR, a targeted immunotherapy for cutaneous T-cell lymphoma, along with late-stage programs such as Mino-Lok for catheter-related bloodstream infections and Halo-Lido for hemorrhoid relief. The company also advances other product candidates aimed at hospital, oncology, and acute-care settings. Headquartered in Cranford, New Jersey, Citius Pharmaceuticals, Inc. plays a role in bringing niche therapies and treatment options to patients and healthcare providers in markets with unmet clinical needs.

Website

Location

11 Commerce Drive

Cranford, NJ, 07016

United States

Social

What share of all stock conversation is about CTXR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 5

Citius Pharmaceuticals, Inc. reports strong commercial progress for LYMPHIR, its FDA-approved cancer treatment for relapsed/refractory cutaneous T-cell lymphoma, with new institutions ordering LYMPHIR increasing 78% quarter-over-quarter.
LYMPHIR is now available in 42 institutions, and the company estimates the CTCL market opportunity exceeds $400M, with a $14.10M market cap and 4.98M shares short, representing 18.48% of the float.
Citius Oncology's commercial momentum is driven by rising repeat vial orders from healthcare providers, alongside near 100% insurer coverage, ahead of their full sales force rollout, with a 78% QoQ surge in ordering accounts across 42 top US cancer centers.

Generated by AI

Sentiment

Of the messages about CTXR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -39.22	52.32% +3.66
Bearish	—	—	100% +39.22	47.68% -3.66

Bullish· Jun 27

$CTXR is expected to have greater highs and will eventually reach its full potential.
Citius Pharmaceuticals, Inc. (CTXR) is a prime acquisition target for CRMD, with a potential deal worth $50-100M.
$CTXR is expected to distribute its shares, with some speculating that it may be acquired by CRMD or distributed to CTOR shareholders.

Bearish· Jun 9

$CTXR is trading at a low average price of $36.75 due to a high risk-to-reward ratio, making it a high-risk investment.
The stock has a history of experiencing pump and dump schemes, leading to significant price drops and potential losses for investors.
Short sellers are actively taking control of the low volume, which could lead to a sell-off and further price declines.

Generated by AI

Topics

Of the messages about CTXR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	80%	87.31%
Analysts	—	—	20%	0.93%
Controversies	—	—	0%	0.93%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	10.84%

Announcements· Jun 9

Citius Pharmaceuticals' subsidiary, Citius Oncology, has entered into a distribution services agreement with Cardinal Health to support the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma.
The agreement with Cardinal Health will provide specialty pharmaceutical distribution services, and the LYMPHIR launch is expected to be supported by the secured J-code and the distribution deal.
Citius Pharmaceuticals has also announced an increase in authorized shares from 26,000,000 to 260,000,000, and the redemption of one share of Series A Preferred Stock for $100.

Technical Analysis· Jun 9

$CTXR is forming a bullish cup and handle pattern, and the author is watching for a potential breakout.
The stock has experienced a significant price increase, with a 170%+ gain, and the author is watching for a potential continuation of the upward momentum.
The author is expecting $CTXR to break $1.75, which could lead to a move to $2.50.

Generated by AI

Community

Of the messages about CTXR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	63.86%
Newcomers	—	—	0%	36.14%

Regulars· May 21

Citius Pharmaceuticals achieves primary and secondary endpoints in Phase 3 trial of Mino-Lok Antibiotic Lock Solution, meeting a statistically significant improvement in time to failure event compared to control arm patients.
The stock price is not holding well despite the positive trial results, with many shares registered to sell near the $1 mark, potentially leading to a 15c pop.
Citius Pharmaceuticals' Phase 3 trial of Mino-Lok Antibiotic Lock Solution has been completed, with the press release issued this morning, and the company's shares are being closely watched for potential swing plays.

Newcomers· Jun 11

New investors are excited about Citius Pharmaceuticals' strategic financing, which will help with the commercial launch of LYMPHIR.
The influx of $15.8M in funding is seen as a positive development for the company's future prospects.
This news is sparking interest in CTXR stock, with some newcomers considering it a potential investment opportunity.

Generated by AI

Citius Pharmaceuticals

Social

Aug 5

Bullish· Jun 27

Bearish· Jun 9

Announcements· Jun 9

Technical Analysis· Jun 9

Regulars· May 21

Newcomers· Jun 11

Citius Pharmaceuticals at Moody Capital conference: launch gains traction

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences

Citius Pharmaceuticals Receives Nasdaq Extension to Regain Compliance

H.C. Wainwright reiterates Citius Pharmaceuticals stock rating at buy

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Also Discussed

Citius Pharmaceuticals, Inc.

Company Information

Location

Citius Pharmaceuticals at Moody Capital conference: launch gains traction

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences

Citius Pharmaceuticals Receives Nasdaq Extension to Regain Compliance

H.C. Wainwright reiterates Citius Pharmaceuticals stock rating at buy

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Also Discussed

Social

Aug 5

Bullish· Jun 27

Bearish· Jun 9

Announcements· Jun 9

Technical Analysis· Jun 9

Regulars· May 21

Newcomers· Jun 11